PubMed Health⌕ Search

Biomedical subjects

M M Lumpkin

Publications and source records attributed to M M Lumpkin.

7 recordsLinked to original sources

International pharmacovigilance: developing cooperation to meet the challenges of the 21st century.

Much has been accomplished internationally in the past decade to harmonise the much of the process of post-marketing drug risk detection. However, formidable challenges exist in harmonising analytical approaches to such data and in leveraging international database resources to improve the quality of such data. In addition, international challenges continue in the arena of drug risk management once a specific risk has been detected. Especially problematic are the questions of appropriate methodology and metrics to assess the public health impact of our risk management techniques. Finally, international challenges remain in the world of drug risk communication to practitioners, dispensers, and patients. The primary challenge confronting us is that of providing easily accessible, understandable, unbiased information on drug risk to these communities so that truly informed decisions about medicines can be made at the individual patient level. Only by meeting internationally these challenges in drug risk detection, management, and communication can our citizens know how to best use these wonderful pharmacological gifts to which we now have access.

Adverse Drug Reaction Reporting Systems↗

The safety of newly approved medicines: do recent market removals mean there is a problem?

The removal of 5 pharmaceuticals from the market in a 12-month period because of unexpected adverse events raised concerns about the adequacy of the drug review process at the US Food and Drug Administration (FDA). Specifically, concerns were raised about improvements in drug review efficiency that significantly reduced FDA review times. We have reviewed the circumstances of the 5 removals to determine whether there was any relationship to the increased efficiencies in the drug review process. When the removed drugs were analyzed by date of approval, no increase in the number of drugs taken off the market was seen, demonstrating that reduced review processing time was not the reason for the cluster of removals. We conclude that the agency's drug review procedures and postmarketing surveillance system after a drug has been marketed are currently adequate but must continually adjust to future challenges.

Adverse Drug Reaction Reporting Systems↗

Ureaplasma urealyticum in semen for artificial insemination: its effect on conception and semen analysis parameters.

Semen specimens from 24 donors in an artificial insemination program--selected for women whose infertile status was determined to be male factor-related and for whom no female factor could be determined--were cultured for the presence of Ureaplasma urealyticum. A life table statistical analysis indicated that conception did not occur sooner in the U. urealyticum-negative group (n = 14) compared with those women inseminated with the U. urealyticum-containing semen (n = 10). In addition, no significant differences were detected in semen analysis count, grade, or motility between semen with or without U. urealyticum. We found no differences in the occurrence of fetal morbidity or mortality in ten conceptions between the women impregnated with Ureaplasma-positive (n = 14) and Ureaplasma-negative (n = 6) semen. Thus, our study does not support the role of U. urealyticum as a cause of male factor-related infertility or early pregnancy loss.

Actuarial Analysis↗